Nadeem Ikhlaque, MD
Hematology & Oncology · Columbus, INNPI 1164477097
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,137 of the $99,277 with a category attached, or 61.6%. 34 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 28.7% of the total. Reporting peaked in 2023 at $23,374 and has fallen 76.9% since, to $5,411 in 2025. Among hematology & oncology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $422.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$29K
- Sanofi$27K
- E.r. Squibb & Sons, L.L.C.$21K
- AstraZeneca$10K
- Rigel Pharmaceuticals, Inc.$3K
- Novocure Inc.$3K
- plus $6K from 28 others
Across 66 payments — averaging $8629.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$456K
- Bristol Myers Squibb$57K
- Genentech, Inc.$34K
- EMD Serono, Inc.$13K
- E.r. Squibb & Sons, L.L.C.$9K
What the payments were for
- Consulting fees$25,10825%
- Speaking & faculty fees$61,13762%
- Travel & lodging$8,8779%
- Food & beverage$3,9704%
- Education$1860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 26 | $28,502 |
| Sanofi | 28 | $27,337 |
| E.r. Squibb & Sons, L.L.C. | 55 | $20,916 |
| AstraZeneca | 15 | $9,956 |
| Rigel Pharmaceuticals, Inc. | 5 | $3,461 |
| Novocure Inc. | 3 | $3,030 |
| Bristol Myers Squibb | 6 | $2,744 |
| Bayer | 2 | $912 |
| EMD Serono, Inc. | 1 | $500 |
| Boehringer Ingelheim | 1 | $400 |
| Genentech USA, Inc. | 21 | $354 |
| Pfizer | 21 | $221 |
| Merck | 13 | $165 |
| Stryker | 1 | $158 |
| Novartis | 7 | $98 |
| Eisai Inc. | 5 | $69 |
| Johnson & Johnson | 2 | $59 |
| Lilly USA, LLC | 4 | $57 |
| Janssen Scientific Affairs, LLC | 1 | $51 |
| Tersera Therapeutics LLC | 1 | $30 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $29 |
| Gilead(2 entities) | 2 | $29 |
| Adaptive Biotechnologies Corporation | 1 | $27 |
| Corcept Therapeutics | 1 | $27 |
| Array Biopharma Inc | 1 | $19 |
| Clovis Oncology, Inc. | 2 | $17 |
| Foundation Medicine, Inc. | 1 | $16 |
| Aurobindo Pharma USA, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Exelixis Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Agios Pharmaceuticals, Inc. | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Incyte Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$99,277 in reported general payments places this provider in the 90th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 65 | $875,222 |
| PomalystPomalidomide | 29 | $653,208 |
| RevlimidLenalidomide | 28 | $397,157 |
| TagrissoOsimertinib Mesylate | 20 | $362,464 |
| Abiraterone Acetate | 70 | $337,339 |
| ImbruvicaIbrutinib | 20 | $325,438 |
| LorbrenaLorlatinib | 11 | $237,945 |
| IbrancePalbociclib | 15 | $236,717 |
| Lenalidomide | 14 | $191,660 |
| BrukinsaZanubrutinib | 11 | $169,041 |
| KisqaliRibociclib Succinate | 15 | $154,860 |
| BraftoviEncorafenib | 15 | $135,124 |
| ZytigaAbiraterone Acetate | 11 | $126,624 |
| EliquisApixaban | 86 | $58,136 |
| XareltoRivaroxaban | 55 | $49,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $13 | $875,22265 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $20,916 | $653,20829 claims |
| PfizerLorbrena, Ibrance, Eliquis | $221 | $532,797112 claims |
| Bristol Myers SquibbRevlimid | $2,744 | $397,15728 claims |
| AstraZenecaTagrisso | $9,956 | $362,46420 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $51 | $337,33970 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $29 | $325,43820 claims |
| Johnson & JohnsonZytiga, Xarelto | $59 | $176,38066 claims |
| NovartisKisqali | $98 | $154,86015 claims |
| Array Biopharma IncBraftovi | $19 | $135,12415 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $15 | $1,20652 claims |
| Lilly USA, LLCOlanzapine | $57 | $21915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Columbus
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Chandler ParkCorydon$661K
- Neel ShahDyer$464K
- Ahad SadiqFort Wayne$430K
- Ajay KandraMadison$408K
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
- Daniel MiltonIndianapolis$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.